Randomized Placebo Controlled Trial of IVIG in autoimmune LGI1/CASPR2 epilepsy,Annals of Neurology

当前位置： X-MOL 学术 › Ann. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Randomized Placebo Controlled Trial of IVIG in autoimmune LGI1/CASPR2 epilepsy
Annals of Neurology ( IF 8.1 ) Pub Date : 2019-12-14 , DOI: 10.1002/ana.25655
Divyanshu Dubey _{1,

2,

3} , Jeffrey Britton _{1,

3} , Andrew McKeon _{1,

2,

3} , Avi Gadoth _{1,

3} , Anastasia Zekeridou _{1,

2,

3} , Sebastian A Lopez Chiriboga _{1,

3} , Michelle Devine _{1,

3} , Jane H Cerhan ₁ , Katie Dunlay _{1,

3} , Jessica Sagen _{1,

3} , Melanie Ramberger ₄ , Patrick Waters ₄ , Sarosh R Irani ₄ , Sean J Pittock _{1,

2,

3}

Affiliation

Drug‐resistant seizures are common in patients with leucine‐rich, glioma‐inactivated 1 (LGI1)‐IgG associated and contactin‐associated protein‐like 2 (CASPR2)‐IgG associated encephalitis. We performed the first randomized double‐blind placebo‐controlled trial to evaluate efficacy of intravenous immunoglobulin (IVIG) in reducing seizure frequency.

中文翻译：

IVIG 在自身免疫性 LGI1/CASPR2 癫痫中的随机安慰剂对照试验

耐药性癫痫发作在富含亮氨酸的胶质瘤灭活 1 (LGI1)-IgG 相关和接触素相关蛋白样 2 (CASPR2)-IgG 相关脑炎患者中很常见。我们进行了第一项随机双盲安慰剂对照试验，以评估静脉注射免疫球蛋白 (IVIG) 在降低癫痫发作频率方面的功效。

更新日期：2019-12-14

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11